Organon & Co. (NYSE:OGN) Shares Acquired by U.S. Capital Wealth Advisors LLC

U.S. Capital Wealth Advisors LLC raised its stake in shares of Organon & Co. (NYSE:OGN) by 42.9% during the fourth quarter, HoldingsChannel reports. The firm owned 247,491 shares of the company’s stock after purchasing an additional 74,242 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Organon & Co. were worth $3,569,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Lindbrook Capital LLC boosted its holdings in shares of Organon & Co. by 348.3% in the 4th quarter. Lindbrook Capital LLC now owns 1,838 shares of the company’s stock valued at $27,000 after acquiring an additional 1,428 shares during the last quarter. Harvest Fund Management Co. Ltd boosted its holdings in shares of Organon & Co. by 495.5% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Organon & Co. in the 3rd quarter valued at $35,000. GAMMA Investing LLC purchased a new stake in Organon & Co. during the fourth quarter worth $38,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in Organon & Co. by 97.7% during the third quarter. EverSource Wealth Advisors LLC now owns 2,246 shares of the company’s stock worth $39,000 after buying an additional 1,110 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Insider Activity

In other Organon & Co. news, insider Kirke Weaver acquired 2,720 shares of the stock in a transaction dated Thursday, February 22nd. The stock was acquired at an average price of $18.36 per share, with a total value of $49,939.20. Following the completion of the purchase, the insider now owns 15,181 shares in the company, valued at approximately $278,723.16. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.17% of the company’s stock.

Organon & Co. Trading Up 0.6 %

Organon & Co. stock traded up $0.11 during midday trading on Friday, hitting $19.61. 3,217,591 shares of the stock were exchanged, compared to its average volume of 2,337,626. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.08. The stock has a market capitalization of $5.04 billion, a price-to-earnings ratio of 4.79, a PEG ratio of 0.92 and a beta of 0.81. The stock’s 50-day simple moving average is $18.19 and its 200 day simple moving average is $15.77.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.14. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a net margin of 16.50% and a negative return on equity of 259.73%. Equities analysts anticipate that Organon & Co. will post 4.1 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Monday, May 13th will be paid a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 5.71%. The ex-dividend date of this dividend is Friday, May 10th. Organon & Co.’s payout ratio is 27.38%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. The Goldman Sachs Group increased their price target on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday. Piper Sandler increased their target price on shares of Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, April 29th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.